Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 470,098 | 371,550 | 393,949 | 180,347 | 378,420 |
| Marketable Securities | 245,607 | 299,676 | 442,891 | 419,264 | 459,243 |
| Receivables | 22,821 | 10,983 | 19,749 | 8,172 | 45,538 |
| TOTAL | $771,280 | $716,230 | $888,858 | $639,710 | $909,871 |
| Non-Current Assets | |||||
| PPE Net | 16,873 | 17,182 | 30,066 | 27,741 | 26,272 |
| Investments And Advances | 0 | 0 | 0 | 17,707 | 79,582 |
| Intangibles | 29,908 | 30,476 | 44,934 | 46,204 | 0 |
| Other Non-Current Assets | 44,172 | 49,261 | 48,934 | 50,162 | 65,761 |
| TOTAL | $90,953 | $96,919 | $123,934 | $141,814 | $171,615 |
| Total Assets | $862,233 | $813,149 | $1,012,792 | $781,524 | $1,081,486 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 8,793 | 10,107 | 11,884 | 12,035 | 22,329 |
| Accrued Expenses | 88,883 | 64,211 | 87,965 | 64,181 | 83,863 |
| TOTAL | $141,160 | $103,463 | $135,069 | $95,823 | $131,909 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,693,179 | 1,708,050 | 1,703,805 | 1,375,314 | 1,373,915 |
| Deferred Revenues | 7,190 | N/A | N/A | N/A | N/A |
| Other Non-Current Liabilities | 34,111 | 47,592 | 46,025 | 54,309 | 38,878 |
| TOTAL | $1,734,587 | $1,750,709 | $1,744,725 | $1,424,542 | $1,407,067 |
| Total Liabilities | $1,875,747 | $1,854,172 | $1,879,794 | $1,520,365 | $1,538,976 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 148,246 | 147,694 | 147,608 | 147,167 | 149,765 |
| Common Shares | 154 | 154 | 154 | 153 | 153 |
| Retained earnings | -1,643,219 | -1,633,363 | -1,436,966 | -1,289,789 | -1,133,854 |
| Other shareholders' equity | 11,591 | -410 | 3,280 | 4,575 | 6,532 |
| TOTAL | $-1,013,514 | $-1,041,023 | $-867,002 | $-738,841 | $-457,490 |
| Total Liabilities And Equity | $862,233 | $813,149 | $1,012,792 | $781,524 | $1,081,486 |